v3.25.2
Summary of Significant Accounting Policies - Narrative (Details)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2025
USD ($)
revenue_source
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
segment
revenue_source
Jun. 30, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2024
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Restricted cash $ 106,337,000 $ 101,545,000 $ 106,337,000 $ 101,545,000   $ 104,215,000
Non-marketable equity and other investments 16,100,000   16,100,000     16,100,000
Impairment of non-marketable equity securities     5,000,000   $ 22,100,000  
Impairment or adjustments of non-marketable securities     0 0    
Contract asset 3,800,000   $ 3,800,000     3,400,000
Number of operating segments | segment     1      
Impairment of goodwill $ 0   $ 0      
Number of revenue sources | revenue_source 4   4      
Revenue recognized in current period, delivered in prior periods $ 8,900,000 $ 15,200,000 $ 18,600,000 24,900,000    
Deferred revenue 60,700,000   60,700,000     41,600,000
Deferred revenue long term $ 6,400,000   6,400,000     6,100,000
Deferred revenue recognized     $ 19,900,000 $ 9,300,000    
Minimum            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Useful life (years) 6 years   6 years      
Minimum | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-07-01            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Remaining performance obligation, expected recognition period 1 year   1 year      
Maximum            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Useful life (years) 12 years   12 years      
Maximum | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-07-01            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Remaining performance obligation, expected recognition period 2 years   2 years      
TwinStrand Biosciences And University Of Washington vs. Guardant Health, Inc.            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Restricted cash $ 105,700,000   $ 105,700,000     $ 103,600,000